UBcare. Co. Ltd (032620) Fair Value & Analysis
Technology · KR · Market cap 149B KRW
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from 8,936 KRW to 4,805 KRW (−46.2%) since Jul 20, 2026. Share price +6.1% over the past month.
A solid business, screening 58% undervalued on our models.
What matters now
- The price is below even our cautious bear case (3,604 KRW). The market is more pessimistic than our downside scenario.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (3,604 KRW to 6,653 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 2,680 KRW – 9,499 KRW · fair‑value band 3,604 KRW – 6,653 KRW · the 3,040 KRW price screens below the 4,805 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
UBcare. Co. Ltd (032620) currently trades at 3,040 KRW, while our model-based Fair Value estimate is 4,805 KRW, implying the stock looks roughly 58.1% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, UBcare. Co. Ltd generated revenue of 128B KRW at a net margin of 5.2%. Revenue grew 28.7% year over year. It earns a return on equity of 116.1%. Fundamentals as of Aug 13, 2026
Our scenario range runs from 3,604 KRW (bear case) to 6,653 KRW (bull case); at 3,040 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at 8% fair-value upside, at 58%, 032620 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (14,400 KRW) versus Economic Profit (1,169 KRW). Highest evidence: Growth DCF (80).
Notify me when 032620 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 23
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
UBcare. Co., Ltd. provides health care solutions in South Korea and internationally. The company offers medical IT services, such as Ysarang, an EMR system for hospital/clinic use; and U Pharm, an integrated management control system for pharmacies, hospitals, clinics, and pharmacy environments; and Big Ysarang, an EMR system for small and medium-sized …
Full company description
UBcare. Co., Ltd. provides health care solutions in South Korea and internationally. The company offers medical IT services, such as Ysarang, an EMR system for hospital/clinic use; and U Pharm, an integrated management control system for pharmacies, hospitals, clinics, and pharmacy environments; and Big Ysarang, an EMR system for small and medium-sized hospitals, as well as customer management and media services. It is also involved in the medical distribution business that suggests products and services, such as high-technology medical equipment/devices for hospitals, clinics, pharmacies, medical e-commerce businesses, and shop-in-shop for health functional food; and provision of customized services. In addition, the company engages in the pharmaceutical marketing business; and provision of U-healthcare solution that offers digitalized hospital solution and healthcare service for personnel. Further, it operates digital hospital in Thailand. Its healthcare network covers 30,000 hospitals/clinics, pharmacies, 17 agencies, and 1.2 million members of healthkorea.net. The company was founded in 1992 and is based in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
UBcare. Co. Ltd reported revenue of 198B KRW in FY2025 versus 112B KRW in FY2021, a compound +15.3%/yr. Reported net income was 37.0B KRW in FY2025, compounding +29.1%/yr from FY2021.
Watch 032620: get an alert when its fair value changes →
Peer Group
Software & IT Services · 34 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Software & IT Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Software & IT Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| KINX, Inc 093320 | 141,900 KRW | 74,800 KRW | -47% |
| 504067 504067 | ₹490.95 | ₹1,754 | +257% |
| Wemade Co 112040 | 17,830 KRW | 9,700 KRW | -46% |
| Gabia Inc 079940 | 43,200 KRW | 33,925 KRW | -21% |
| Hancom Inc 030520 | 17,110 KRW | 44,234 KRW | +159% |
| Webzen Inc 069080 | 11,830 KRW | 12,748 KRW | +8% |
| NEOWIZ 095660 | 18,130 KRW | 46,407 KRW | +156% |
| Wemade Max Co 101730 | 4,560 KRW | 1,014 KRW | -78% |
| GalaxiaMoneytree Co 094480 | 5,250 KRW | 3,778 KRW | -28% |
| DAEA TI Co 045390 | 2,635 KRW | 4,940 KRW | +87% |
Compare UBcare. Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is UBcare. Co. Ltd (032620) overvalued or undervalued?
What is the fair value of 032620?
What is the quality score of 032620?
What is the revenue of UBcare. Co. Ltd (032620)?
What is the net profit margin of 032620?
Does UBcare. Co. Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track UBcare. Co. Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.